[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO2019010524A2 - Plataforma de identificación de péptidos inmunogénicos basada en población - Google Patents

Plataforma de identificación de péptidos inmunogénicos basada en población

Info

Publication number
CO2019010524A2
CO2019010524A2 CONC2019/0010524A CO2019010524A CO2019010524A2 CO 2019010524 A2 CO2019010524 A2 CO 2019010524A2 CO 2019010524 A CO2019010524 A CO 2019010524A CO 2019010524 A2 CO2019010524 A2 CO 2019010524A2
Authority
CO
Colombia
Prior art keywords
population
methods
immunogenic peptide
identification platform
peptide identification
Prior art date
Application number
CONC2019/0010524A
Other languages
English (en)
Inventor
József Toth
Orsolya Lorincz
Eszter Somogyi
Mónika Megyesi
Julianna Lisziewicz
Levente Molnár
Enikő R Tőke
Zsolt Csiszovszki
Katalin Pántya
Original Assignee
Treos Bio Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61386864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019010524(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP17159243.9A external-priority patent/EP3370065A1/en
Priority claimed from EP17159242.1A external-priority patent/EP3369431A1/en
Priority claimed from GBGB1703809.2A external-priority patent/GB201703809D0/en
Application filed by Treos Bio Zrt filed Critical Treos Bio Zrt
Publication of CO2019010524A2 publication Critical patent/CO2019010524A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La descripción se refiere a métodos para identificar fragmentos de un polipéptido que son inmunogénicos para un sujeto humano específico, métodos para preparar composiciones farmacéuticas que comprenden dichos fragmentos de polipéptido, composiciones farmacéuticas que comprenden dichos fragmentos de polipéptido y métodos de tratamiento que utilizan dichas composiciones. Los métodos comprenden identificar un fragmento del polipéptido que se une a múltiples HLA de sujetos individuales.
CONC2019/0010524A 2017-03-03 2019-09-26 Plataforma de identificación de péptidos inmunogénicos basada en población CO2019010524A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17159243.9A EP3370065A1 (en) 2017-03-03 2017-03-03 Immunogenic peptides
EP17159242.1A EP3369431A1 (en) 2017-03-03 2017-03-03 Vaccine
GBGB1703809.2A GB201703809D0 (en) 2017-03-09 2017-03-09 Vaccine
PCT/EP2018/055232 WO2018158457A1 (en) 2017-03-03 2018-03-02 Population-based immunogenic peptide identification platform

Publications (1)

Publication Number Publication Date
CO2019010524A2 true CO2019010524A2 (es) 2020-01-17

Family

ID=61386864

Family Applications (3)

Application Number Title Priority Date Filing Date
CONC2019/0010524A CO2019010524A2 (es) 2017-03-03 2019-09-26 Plataforma de identificación de péptidos inmunogénicos basada en población
CONC2019/0010503A CO2019010503A2 (es) 2017-03-03 2019-09-26 Plataforma de identificación de péptidos inmunogénicos personalizada
CONC2019/0010698A CO2019010698A2 (es) 2017-03-03 2019-09-27 Vacunas de peptidos

Family Applications After (2)

Application Number Title Priority Date Filing Date
CONC2019/0010503A CO2019010503A2 (es) 2017-03-03 2019-09-26 Plataforma de identificación de péptidos inmunogénicos personalizada
CONC2019/0010698A CO2019010698A2 (es) 2017-03-03 2019-09-27 Vacunas de peptidos

Country Status (16)

Country Link
US (9) US20180264095A1 (es)
EP (3) EP3589954A1 (es)
JP (4) JP2020510698A (es)
KR (4) KR102591136B1 (es)
CN (3) CN110651189B (es)
AU (3) AU2018228786A1 (es)
BR (3) BR112019018307A2 (es)
CA (3) CA3054861A1 (es)
CL (4) CL2019002534A1 (es)
CO (3) CO2019010524A2 (es)
IL (3) IL268919B2 (es)
MA (3) MA47677A (es)
MX (3) MX2019010461A (es)
SG (3) SG11201907402SA (es)
WO (3) WO2018158455A1 (es)
ZA (2) ZA201904725B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7362249B2 (ja) * 2015-03-20 2023-10-17 チルドレンズ ナショナル メディカル センター ナイーブｔ細胞集団からのウイルスまたは他の抗原に特異的なｔ細胞の生成
KR102591136B1 (ko) 2017-03-03 2023-10-17 트레오스 바이오 리미티드 집단 기반 면역원성 펩타이드 확인 플랫폼
AU2019334437A1 (en) 2018-09-04 2021-03-18 Treos Bio Limited Peptide vaccines
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
TW202028224A (zh) * 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
TW202039535A (zh) * 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102159921B1 (ko) * 2020-03-24 2020-09-25 주식회사 테라젠바이오 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램
KR20230017373A (ko) 2020-04-03 2023-02-03 펩티씨 백신즈 리미티드 코로나바이러스 백신
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
WO2021213687A1 (en) * 2020-04-20 2021-10-28 NEC Laboratories Europe GmbH A method and a system for optimal vaccine design
CN112048001B (zh) * 2020-09-08 2022-04-05 南方科技大学 一种肿瘤新生抗原多肽及其应用
KR102278727B1 (ko) * 2020-09-16 2021-07-19 주식회사 테라젠바이오 대상 암 조직 및 세포 유리형 dna 유래 펩타이드 서열 및 hla 클래스 ii 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램
JPWO2023017768A1 (es) 2021-08-10 2023-02-16
TW202322137A (zh) 2021-10-04 2023-06-01 日商日本電氣股份有限公司 管理方法、管理系統及電子健康紀錄系統
WO2023059606A1 (en) * 2021-10-06 2023-04-13 Cancervax, Inc. Methods and compositions for cancer treatment
WO2023211024A1 (ko) * 2022-04-27 2023-11-02 포항공과대학교 산학협력단 시험관 진화 기반 핫스팟 유래 펩타이드-핵산 하이브리드 분자 제조방법
CN115785203B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标10及其用途
GB202216453D0 (en) 2022-11-04 2022-12-21 Lisziewicz Julianna Identification of antigens which induce t-cell responses

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
AU2203797A (en) 1996-03-11 1997-10-01 Epimmune, Inc. Peptides with increased binding affinity for hla molecules
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US7227002B1 (en) * 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
WO2004022709A2 (en) 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
EP1618127B1 (en) 2003-04-10 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic composition comprising a spike protein of the SARS coronavirus
US20050100883A1 (en) 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
KR20060129393A (ko) 2004-01-20 2006-12-15 아이치 프레펙츄러 ＨＬＡ－Ａ2402-제한 Ｅｐ－ＣＡＭ 특이적 ＣＴＬ에인식되는 에피토프/펩티드 및 그 용도
CA2566506A1 (en) 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
EP2657338B1 (en) 2005-01-25 2015-07-08 NEC Corporation HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide
CA2593714C (en) 2005-02-04 2013-09-10 Survac Aps Survivin peptide vaccine
CN100402554C (zh) * 2005-02-25 2008-07-16 李玉新 睾丸特异性蛋白50人源抗体的制备及用途
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
GB0520067D0 (en) 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
EP2089423B1 (en) 2006-09-21 2016-10-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
EP2084267B1 (en) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2042600A1 (en) 2007-09-28 2009-04-01 Commissariat A L'energie Atomique A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications
CA2719964C (en) 2008-03-31 2016-10-04 Bioimmulance Co., Ltd. Partial peptide of survivin presented on mhc class ii molecule and use thereof
NO2119726T3 (es) 2008-05-14 2015-05-23
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB0818065D0 (en) * 2008-10-02 2008-11-05 Cancer Rec Tech Ltd Immunogenic peptides and uses thereof
US20120244145A1 (en) * 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
US20170039314A1 (en) * 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2012051282A2 (en) 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
JP2016540042A (ja) * 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
WO2015164798A1 (en) 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
AU2015314776A1 (en) 2014-09-14 2017-04-06 Washington University Personalized cancer vaccines and methods therefor
CA2969231C (en) * 2014-12-03 2021-06-08 Verik Bio, Inc. Identification, selection and use of high curative potential t cell epitopes
EP3286361A4 (en) 2015-04-23 2019-05-08 Nantomics, LLC CANCER NEO-EPITOPES
US11090332B2 (en) 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
AU2016339035A1 (en) * 2015-10-12 2018-05-10 Nantomics, Llc Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors
GB201604755D0 (en) 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
JP2020503840A (ja) 2016-10-07 2020-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｈｌａ拘束性ｖｇｌｌ１ペプチドおよびその使用
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
KR102591136B1 (ko) 2017-03-03 2023-10-17 트레오스 바이오 리미티드 집단 기반 면역원성 펩타이드 확인 플랫폼
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
CN111886027A (zh) 2017-12-28 2020-11-03 磨石肿瘤生物技术公司 靶向共同抗原的抗原结合蛋白
EP3796923A4 (en) 2018-05-18 2022-03-09 Children's National Medical Center IMPROVED TARGETED T-CELL THERAPY
WO2019222762A1 (en) 2018-05-18 2019-11-21 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
AU2019334437A1 (en) 2018-09-04 2021-03-18 Treos Bio Limited Peptide vaccines
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
EP3908292A4 (en) 2019-01-07 2023-01-04 Children's National Medical Center ENHANCED TARGETED T LYMPHOCYTE THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA
CA3126066A1 (en) 2019-01-07 2020-07-16 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine

Also Published As

Publication number Publication date
MA47677A (fr) 2020-01-08
US11213578B2 (en) 2022-01-04
CL2019002534A1 (es) 2020-02-07
CO2019010503A2 (es) 2020-01-17
CN110651188B (zh) 2024-02-02
WO2018158455A1 (en) 2018-09-07
US20220111024A1 (en) 2022-04-14
US20190240302A1 (en) 2019-08-08
JP2020511672A (ja) 2020-04-16
BR112019018312A2 (pt) 2020-03-31
CL2019002532A1 (es) 2020-02-07
US20180250399A1 (en) 2018-09-06
CN110651189B (zh) 2024-10-25
CN110651188A (zh) 2020-01-03
CN110651189A (zh) 2020-01-03
SG11201907524UA (en) 2019-09-27
IL268919B1 (en) 2023-06-01
KR102549625B1 (ko) 2023-06-28
CN110621334A (zh) 2019-12-27
JP2020510698A (ja) 2020-04-09
US10213497B2 (en) 2019-02-26
MX2019010459A (es) 2020-01-09
JP2023051941A (ja) 2023-04-11
US11426452B2 (en) 2022-08-30
AU2018228785B2 (en) 2024-09-26
BR112019018313A2 (pt) 2020-05-19
AU2018228785A1 (en) 2019-08-01
ZA201904723B (en) 2024-01-31
US20220111025A1 (en) 2022-04-14
JP2020514413A (ja) 2020-05-21
JP7437939B2 (ja) 2024-02-26
WO2018158456A1 (en) 2018-09-07
EP3589951A1 (en) 2020-01-08
WO2018158457A1 (en) 2018-09-07
KR20240156643A (ko) 2024-10-30
IL268920A (en) 2019-10-31
BR112019018307A2 (pt) 2020-03-31
US20180264094A1 (en) 2018-09-20
EP3589310A1 (en) 2020-01-08
IL268919B2 (en) 2023-10-01
ZA201904725B (en) 2024-01-31
KR102591136B1 (ko) 2023-10-17
AU2018226566A1 (en) 2019-08-01
US20220072114A1 (en) 2022-03-10
US11628211B2 (en) 2023-04-18
IL268917B (en) 2022-12-01
IL268919A (en) 2019-10-31
CA3054861A1 (en) 2018-09-07
US20220031823A1 (en) 2022-02-03
US20230405100A1 (en) 2023-12-21
IL268917B2 (en) 2023-04-01
MA47683A (fr) 2020-01-08
CL2019002533A1 (es) 2020-02-07
MX2019010460A (es) 2020-01-09
CL2022002836A1 (es) 2023-06-16
MA47678A (fr) 2021-05-26
CA3054866A1 (en) 2018-09-07
AU2018228786A1 (en) 2019-08-01
IL268917A (en) 2019-10-31
SG11201907402SA (en) 2019-09-27
CA3054871A1 (en) 2018-09-07
MX2019010461A (es) 2020-01-09
KR20190134636A (ko) 2019-12-04
SG11201906765UA (en) 2019-08-27
US20180264095A1 (en) 2018-09-20
KR102723248B1 (ko) 2024-10-29
CO2019010698A2 (es) 2020-01-17
KR20190133177A (ko) 2019-12-02
EP3589954A1 (en) 2020-01-08
KR20190133010A (ko) 2019-11-29

Similar Documents

Publication Publication Date Title
CO2019010524A2 (es) Plataforma de identificación de péptidos inmunogénicos basada en población
CL2023002421A1 (es) Neoantígenos compartidos
CL2021001744A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CL2019002941A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer. (divisional solicitud 201801531)
UY36458A (es) Anticuerpos humanos para hemaglutinina influenza.
BR112017017293A2 (pt) método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina
CL2017000311A1 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CY1122615T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
CR20170554A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos.
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
CL2019002944A1 (es) Nuevos péptidos y combinación de péptidos para el uso de la inmunoterapia contra varios tipos de cáncer. (divisional solicitud 201801533)
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
ES2721159T3 (es) Antígenos asociados a tumor independientes de MHC novedosos
CL2020001781A1 (es) Un péptido de nudo de cistina (ckp) de origen no natural que se une a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (lrp6) humana. (divisional solicitud 201800668)
CO2021004035A2 (es) Ensayo de cribado de cáncer inmunogenético
EA201992059A1 (ru) Платформа для идентификации иммуногенных пептидов популяционного уровня
EA201791389A1 (ru) Способы и композиции антител, направленных против bmp6